Therapeutic Solutions International Subsidiary Campbell Neurosciences Reports Positive Preclinical Data in Animal Model of Schizophrenia Using Proprietary Universal Donor Mesenchymal Stem Cell

Therapeutic Solutions International, Inc. and its subsidiary Campbell Neurosciences announced new data covered by its previously filed patents supporting the use of mesenchymal based stem cell therapy for schizophrenia.